1. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2. |
陈万青, 李贺, 孙可欣, 等. 2014年中国分地区恶性肿瘤发病和死亡分析. 中华肿瘤杂志, 2018, 27(1): 1-14.
|
3. |
Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study. Int J Cancer, 2015, 136(8): 1921-1930.
|
4. |
Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol, 2017, 12(7): 1109-1121.
|
5. |
Robertson KD. DNA methylation and chromatin-unraveling the tangled web. Oncogene, 2002, 21(35): 5361-5367.
|
6. |
Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell, 2012, 150(1): 12-27.
|
7. |
Song L, Yu H, Li Y. Diagnosis of lung cancer by SHOX2 gene methylation assay. Mol Diagn Ther, 2015, 19(3): 159-167.
|
8. |
Huang YZ, Wu W, Wu K, et al. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 2015, 15(23): 10325-10328.
|
9. |
Tuo L, Sha S, Huayu Z, et al. P16(INK4a) gene promoter methylation as a biomarker for the diagnosis of non-small cell lung cancer: An updated meta-analysis. Thorac Cancer, 2018, 9(8): 1032-1040.
|
10. |
Pu W, Geng X, Chen S, et al. Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma. J Cancer, 2016, 7(15): 2280-2289.
|
11. |
Chung JH, Lee HJ, Kim BH, et al. DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch, 2011, 459(2): 201-211.
|
12. |
Nawaz I, Qiu X, Wu H, et al. Development of a multiplex methylation specific PCR suitable for (early) detection of non-small cell lung cancer. Epigenetics, 2014, 9(8): 1138-1148.
|
13. |
Zhang Y, Wang R, Song H, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett, 2011, 303(1): 21-28.
|
14. |
Ma Y, Bai Y, Mao H, et al. A panel of promoter methylation markers for invasive and noninvasive early detection of NSCLC using a quantum dots-based FRET approach. Biosens Bioelectron, 2016, 85: 641-648.
|
15. |
Geng J, Sun J, Lin Q, et al. Methylation status of NEUROG2 and NID2 improves the diagnosis of stageⅠNSCLC. Oncol Lett, 2012, 3(4): 901-906.
|
16. |
Gao L, Xie E, Yu T, et al. Methylated APC and RASSF1A in multiple specimens contribute to the differential diagnosis of patients with undetermined solitary pulmonary nodules. J Thorac Dis, 2015, 7(3): 422-432.
|
17. |
Licchesi JD, Westra WH, Hooker CM, et al. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res, 2008, 14(9): 2570-2578.
|
18. |
Millares L, Serra M, Andreo F, et al. Assessment of methylation status of locoregional lymph nodes in lung cancer using EBUS-NA. Clin Exp Metastasis, 2015, 32(7): 637-646.
|
19. |
van der Drift MA, Hol BE, Klaassen CH, et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer, 2010, 68(2): 283-287.
|
20. |
Weiss G, Schlegel A, Kottwitz D, et al. Validation of the SHOX2/PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. J Thorac Oncol, 2017, 12(1): 77-84.
|
21. |
Weiss G, Hasinger O, Esche S, et al. 31PD DNA methylation of SHOX2 and PTGER4 as a plasma-based tool to differentiate between patients with malignant and benign lung disease. J Thorac Oncol, 2016, 11(4): S68.
|
22. |
Hulbert A, Jusue-Torres I, Stark A, et al. Early detection of lung cancer using DNA promoter hypermethylation in plasma and sputum. Clin Can Res, 2017, 23(8): 1998.
|
23. |
Ren M, Wang C, Sheng D, et al. Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis. Ann Diagn Pathol, 2017, 27: 57-61.
|
24. |
Zhang C, Yu W, Wang L, et al. DNA methylation analysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis. J Cancer, 2017, 8(17): 3585-3591.
|
25. |
Hubers AJ, Prinsen CF, Sozzi G, et al. Molecular sputum analysis for the diagnosis of lung cancer. Br J Cancer, 2013, 109(3): 530-537.
|
26. |
Hubers AJ, Heideman DA, Duin S, et al. DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2 years. J Clin Pathol, 2017, 70(3): 250-254.
|
27. |
Hubers AJ, Heideman DAM, Burgers SA, et al. DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach. Br J Cancer, 2015, 112(6): 1105-1113.
|
28. |
Hubers AJ, van der Drift MA, Prinsen CF, et al. Methylation analysis in spontaneous sputum for lung cancer diagnosis. Lung Cancer, 2014, 84(2): 127-133.
|
29. |
Liloglou T, Bediaga NG, Brown BR, et al. Epigenetic biomarkers in lung cancer. Cancer Lett, 2014, 342(2): 200-212.
|
30. |
Hubers AJ, Heideman DAM, Herder GJM, et al. Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer. J Clin Pathol, 2012, 65(6): 541.
|